Literature DB >> 22754185

Serum paraoxonase levels in patients with acute liver disease.

C M Bindu, Usha Anand, C V Anand.   

Abstract

Paraoxonase is an anti-oxidant enzyme, which circulates in the plasma, tightly bound to HDL. This enzyme is known to be synthesized in the liver. This study was carried out in order to ascertain the diagnostic utility of this enzyme in acute liver disease. Serum basal as well as salt (NaCl) stimulated paraoxonase was estimated in 50 patients with an established diagnosis of acute liver disease and also in 50 healthy blood donors. Paraoxonase levels were significantly lower in patients as compared with controls (P < 0.05). The 'receiver operating characteristic' plot showed that this enzyme has a high degree of sensitivity and specificity for the diagnosis acute liver disease. Serum PON is likely to emerge as an additional test of liver function, as it encompasses three different attributes of hepatic function namely, synthetic capacity, detoxication and secretory functions.

Entities:  

Keywords:  Basal PON; Liver function tests; Paraoxonase; Salt-stimulated PON

Year:  2011        PMID: 22754185      PMCID: PMC3162951          DOI: 10.1007/s12291-010-0097-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  13 in total

1.  Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis.

Authors:  N Ferré; J Camps; M Cabré; A Paul; J Joven
Journal:  Metabolism       Date:  2001-09       Impact factor: 8.694

2.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.

Authors:  Dragomir I Draganov; John F Teiber; Audrey Speelman; Yoichi Osawa; Roger Sunahara; Bert N La Du
Journal:  J Lipid Res       Date:  2005-03-16       Impact factor: 5.922

Review 4.  HDL, its enzymes and its potential to influence lipid peroxidation.

Authors:  M I Mackness; P N Durrington
Journal:  Atherosclerosis       Date:  1995-06       Impact factor: 5.162

5.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

6.  Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.

Authors:  M Aviram; M Rosenblat; S Billecke; J Erogul; R Sorenson; C L Bisgaier; R S Newton; B La Du
Journal:  Free Radic Biol Med       Date:  1999-04       Impact factor: 7.376

7.  Human liver paraoxonase (PON1): subcellular distribution and characterization.

Authors:  M C Gonzalvo; F Gil; A F Hernandez; L Rodrigo; E Villanueva; A Pla
Journal:  J Biochem Mol Toxicol       Date:  1998       Impact factor: 3.642

8.  Decrease of serum paraoxonase activity in chronic renal failure.

Authors:  T F Dantoine; J Debord; J P Charmes; L Merle; P Marquet; G Lachatre; C Leroux-Robert
Journal:  J Am Soc Nephrol       Date:  1998-11       Impact factor: 10.121

9.  Serum adenosine deaminase, 5' nucleotidase and malondialdehyde in acute infective hepatitis.

Authors:  K Pratibha; Usha Anand; Rajni Agarwal
Journal:  Indian J Clin Biochem       Date:  2004-07

10.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R.

Authors:  M Aviram; S Billecke; R Sorenson; C Bisgaier; R Newton; M Rosenblat; J Erogul; C Hsu; C Dunlop; B La Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

View more
  1 in total

1.  Association between PON1 rs662 polymorphism and coronary artery disease.

Authors:  T Liu; X Zhang; J Zhang; Z Liang; W Cai; M Huang; C Yan; Z Zhu; Y Han
Journal:  Eur J Clin Nutr       Date:  2014-06-11       Impact factor: 4.016

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.